Abstract
While several retrospective studies have suggested a possible benefit of lymph node dissection (LND) for patients with clinically node-positive renal cell carcinoma (RCC), the value of LND in patients with clinically node-negative RCC has remained uncertain. LND undoubtedly improves the accuracy of staging and provides better prognostic information; however, much debate surrounds the impact of LND on progression-free and overall survival in patients with RCC. Additionally, the question remains as to whether LND at nephrectomy is associated with increased morbidity. The final results of the European Organisation for Research and Treatment of Cancer (EORTC) randomized phase III trial 30881 demonstrate that complete LND at nephrectomy does not affect the survival of patients with clinical N0M0 RCC. Importantly, no increase in morbidity was noted in patients who underwent an extended LND compared with no LND, indicating that the performance of LND is unlikely to increase the risk to the patient.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Canfield SE et al. (2006) Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease (clinical stage TxN1–2M0): the impact of aggressive surgical resection on patient outcome. J Urol 175: 864–869
Blom JHM et al. (2009) Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. Eur Urol 55: 28–34
Giuliani L (1983) Lymphadenectomy and renal cell carcinoma: why is there so much controversy? Eur Urol 9: 374
Terrone C et al. (2006) Reassessing the current TNM lymph node staging for renal cell carcinoma. Eur Urol 49: 324–331
Pantuck AJ et al. (2003) Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. J Urol 169: 2076–2083
Herrlinger A et al. (1991) What are the benefits of extended dissection of the regional renal lymph nodes in the therapy of renal cell carcinoma. J Urol 146: 1224–1227
Blute ML et al. (2004) A protocol for performing extended lymph node dissection using primary tumor pathological features for patients treated with radical nephrectomy for clear cell renal cell carcinoma. J Urol 172: 465–469
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
CG Wood declared that he has acted as a consultant for Ethicon and Pfizer, and has received speakers' bureau honoraria from Pfizer. SH Culp declared no competing interests.
Rights and permissions
About this article
Cite this article
Culp, S., Wood, C. Should patients undergoing surgery for renal cell carcinoma have a lymph node dissection?. Nat Rev Urol 6, 126–127 (2009). https://doi.org/10.1038/ncpuro1312
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncpuro1312
This article is cited by
-
Role of lymph node dissection in managing urologic cancers
International Journal of Clinical Oncology (2011)